• Donate
  • Contact


back to news

CSRO Responds to RFI Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs

Posted: July 16, 2018

The Coalition of State Rheumatology Organization’s (CSRO) has submitted their comments regarding the Request for Information (RFI) by the Department of Health and Human Services. The request was made after the President issued his “Blueprint to Lower Drug Prices” back in early May.

The Department of Health and Human Services has been requesting meetings with drug manufacturers and pharmacy benefit managers to discuss changes to the system. It is expected that the Center for Medicare and Medicaid Innovation (CMMI) will release a Rule in response to the feedback gathered from the RFI and meetings with stakeholders within the next couple of months.

In preparation, the CSRO has been gathering feedback from the rheumatology community and its patient organizations.

CSRO RFI Response Highlights:

  • Part B Competitive Acquisition Program
  • Moving drugs from Part B to Part D
  • Reducing the impact of manufacturer rebates to Pharmacy Benefit Managers
  • Copay discount cards
  • Incentives to lower or not increase list prices
  • Fiduciary duty for Pharmacy Benefit Managers
  • Federal Preemption of Pharmacy Gag Clause Laws
  • Biosimilars
Read Full Comments

We use cookies so that we can remember you and understand how you use our site. If you do not agree with our use of cookies, please change the current settings found in our Cookie Policy. Otherwise, you agree to the use of the cookies as they are currently set. To learn more, please visit our Privacy Policy.